Clinical data integrations: Secure API layers that automatically pull diagnostic lab results directly into the patients medical record
1,2 Oral semaglutide became the first FDA-approved GLP-1RA in tablet form for the treatment of T2D in September 2019, 3,4 and it is now approved in the European Union, United Kingdom, and Japan
Hypothalamic Appetite Regulation: Investigating the activation of GLP-1 receptors in the arcuate nucleus to study reductions in caloric intake and body mass
Here, additional data on the preventive health benefits of treating obesity will be key (e.g., SELECT trial for semaglutide) A company with asset(s) featuring compelling preclinical and clinical data demonstrating the above described profile could be positioned well to raise venture capital, even in todays challenging private financing market, and attract M&A activity from giants like Novo Nordisk and Eli Lilly
Better than I thought it would be
3 Feed-forward cognitive control of satiation